Aromatase inhibitors have been shown to reduce oestrogen levels in postmenopausal women with breast cancer, though obese women still had more recurrences and poorer prognoses than non-obese women [98,99,100,101], indicating that there is more to the link between obesity and cancer than just oestrogen. Here, CYP19A1 is linked to obesity disorder.